MaxCyte (MXCT) Competitors $3.49 +0.16 (+4.80%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MXCT vs. MGTX, MGNX, ARCT, HRTX, HBIO, EVH, LZ, TASK, CTOS, and FVRRShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include MeiraGTx (MGTX), MacroGenics (MGNX), Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Harvard Bioscience (HBIO), Evolent Health (EVH), LegalZoom.com (LZ), TaskUs (TASK), Custom Truck One Source (CTOS), and Fiverr International (FVRR). MaxCyte vs. MeiraGTx MacroGenics Arcturus Therapeutics Heron Therapeutics Harvard Bioscience Evolent Health LegalZoom.com TaskUs Custom Truck One Source Fiverr International MeiraGTx (NASDAQ:MGTX) and MaxCyte (NASDAQ:MXCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment. Is MGTX or MXCT more profitable? MaxCyte has a net margin of -78.36% compared to MeiraGTx's net margin of -633.05%. MaxCyte's return on equity of -16.00% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets MeiraGTx-633.05% -146.38% -53.05% MaxCyte -78.36%-16.00%-13.93% Do analysts recommend MGTX or MXCT? MeiraGTx currently has a consensus target price of $23.50, suggesting a potential upside of 303.78%. MaxCyte has a consensus target price of $8.67, suggesting a potential upside of 148.33%. Given MeiraGTx's higher probable upside, equities analysts plainly believe MeiraGTx is more favorable than MaxCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00MaxCyte 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, MGTX or MXCT? MaxCyte has higher revenue and earnings than MeiraGTx. MaxCyte is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeiraGTx$14.02M32.44-$84.03M-$1.21-4.81MaxCyte$41.29M8.92-$37.92M-$0.34-10.26 Does the MarketBeat Community believe in MGTX or MXCT? MeiraGTx received 180 more outperform votes than MaxCyte when rated by MarketBeat users. However, 84.62% of users gave MaxCyte an outperform vote while only 71.54% of users gave MeiraGTx an outperform vote. CompanyUnderperformOutperformMeiraGTxOutperform Votes19171.54% Underperform Votes7628.46% MaxCyteOutperform Votes1184.62% Underperform Votes215.38% Do institutionals & insiders have more ownership in MGTX or MXCT? 67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 8.4% of MeiraGTx shares are owned by company insiders. Comparatively, 3.0% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, MGTX or MXCT? MeiraGTx has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Does the media refer more to MGTX or MXCT? In the previous week, MeiraGTx had 8 more articles in the media than MaxCyte. MarketBeat recorded 8 mentions for MeiraGTx and 0 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.50 beat MeiraGTx's score of -0.28 indicating that MaxCyte is being referred to more favorably in the news media. Company Overall Sentiment MeiraGTx Neutral MaxCyte Positive SummaryMaxCyte beats MeiraGTx on 11 of the 17 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$351.26M$4.28B$5.06B$8.89BDividend YieldN/A1.65%4.97%4.06%P/E Ratio-10.2644.6089.0213.30Price / Sales8.9259.971,207.2881.01Price / CashN/A25.5039.1736.03Price / Book1.733.086.085.74Net Income-$37.92M$139.66M$119.07M$225.93M7 Day Performance1.45%-2.11%-1.84%-1.32%1 Month Performance-7.18%14.92%-3.65%0.60%1 Year Performance-19.40%35.25%31.62%26.23% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyte2.9804 of 5 stars$3.49+4.8%$8.67+148.3%-22.4%$351.26M$41.29M-10.26143MGTXMeiraGTx4.3119 of 5 stars$5.82-2.7%$23.50+303.8%+2.8%$467.36M$14.02M0.00300Analyst ForecastMGNXMacroGenics3.8684 of 5 stars$3.28-5.7%$7.63+132.5%-57.0%$218.42M$58.75M0.00430ARCTArcturus Therapeutics2.0511 of 5 stars$16.17-10.5%$71.40+341.6%-33.7%$489.19M$142.47M-7.28180HRTXHeron Therapeutics3.9688 of 5 stars$1.12-5.9%$5.67+406.0%-13.8%$180.99M$137.74M-6.22300Analyst DowngradeShort Interest ↓HBIOHarvard Bioscience1.566 of 5 stars$2.16+5.4%N/A-48.8%$89.41M$112.25M0.00490Positive NewsEVHEvolent Health3.5821 of 5 stars$11.29-5.5%$28.90+156.0%-61.3%$1.39B$1.96B0.004,700Analyst ForecastLZLegalZoom.com2.3401 of 5 stars$7.63+1.2%$8.67+13.6%-33.2%$1.30B$660.73M58.701,190TASKTaskUs1.7046 of 5 stars$14.30+0.9%$16.43+14.9%+14.2%$1.27B$924.36M24.2448,200CTOSCustom Truck One Source1.0469 of 5 stars$5.18+2.4%$5.63+8.6%-8.8%$1.18B$1.87B0.002,580FVRRFiverr International1.3205 of 5 stars$30.69+1.1%$31.60+3.0%+27.9%$1.17B$361.38M118.04790 Related Companies and Tools Related Companies MeiraGTx Alternatives MacroGenics Alternatives Arcturus Therapeutics Alternatives Heron Therapeutics Alternatives Harvard Bioscience Alternatives Evolent Health Alternatives LegalZoom.com Alternatives TaskUs Alternatives Custom Truck One Source Alternatives Fiverr International Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MXCT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
